You are here: Acridine-raw-material NewsViews

Halaven drug therapy treatment liposarcoma

US FDA on January 28, 2016 approved chemotherapeutic drug Halaven (eribulin mesylate, mesylate Ereli Brin), the treatment of liposarcoma (STS, a particular type of soft tissue sarcoma), can not pass surgery (resection) or late (transfer sex) tumors. This treatment has been approved in patients previously received anthracycline chemotherapy.


FDA Center for Drug Evaluation and Research Office of Hematology and Oncology Products Director Richard Pazdur, M.D. said, Halaven is the first approved drug treatment of liposarcoma and demonstrate improved survival time. FDA review of clinical trial data showed Halaven increase the overall survival of about seven months, there is provided a drug clinically meaningful to patients.


Soft tissue sarcoma (STS) is a disease of the body's soft tissues, including muscles, tendons, fat, blood vessels, lymphatic vessels, nerves and tissues around joints. Liposarcoma is a specific type of STS occurs in adipocytes. STS can be anywhere in the body in the formation, the most common site is the head, neck, arms, legs, torso and abdomen. According to the US National Cancer Institute for Statistics, in 2014, an estimated 12,000 in the United States diagnosed with STS.


Halaven clinical trials of safety and efficacy study of 143 cases of advanced fat meat (unresectable or has spread to nearby lymph nodes (late) or (metastatic), and has begun chemotherapy) were enrolled. When participants began to spread disease or can not tolerate the side effects of treatment, and some use Halaven chemotherapy, and some use of dacarbazine (dacarbazine) chemotherapy do comparison. This study aims a long (overall survival, OS) measured the survival of patients, receiving Halaven chemotherapy median OS was 15.6 months (dacarbazine, 8.4 months).